Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

Certolizumab pegol (CZP), an anti–tumor necrosis factor α agent, is an effective therapy for Crohn's disease (CD). A population pharmacokinetic (PK) analysis of subcutaneously administered CZP was performed using data from 2157 CD patients from 9 separate studies. The aim was to determine which...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2015-08, Vol.55 (8), p.866-874
Hauptverfasser:	Wade, Janet R., Parker, Gerry, Kosutic, Gordana, Feagen, Brian G., Sandborn, William J., Laveille, Christian, Oliver, Ruth
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over anti-TNF Body Mass Index Body Surface Area Body Weight Bowel disease C-Reactive Protein - analysis certolizumab pegol Certolizumab Pegol - immunology Certolizumab Pegol - pharmacokinetics covariates Crohn Disease - blood Crohn Disease - immunology Crohn Disease - metabolism Crohn's disease Female Humans Immunosuppressive Agents - immunology Immunosuppressive Agents - pharmacokinetics Male Middle Aged Models, Biological NONMEM Pharmacometric Pharmacometrics Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!